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Objectives: The diagnosis of obstructive lung
disease (OLD) may be overlooked because of the
poor correlation between the intensity of symp-
toms and the severity of airway obstruction (AO).
Undiagnosed airflow obstruction (UDAO) is asso-
ciated with health impairment and mortality.
Questions remain such as the reasons for its occur-
rence and the underlying diseases. In a pulmonolo-
gist’s private practice, the objectives were to detect
UDAO in the absence of dyspnoea, cough and
wheezing, to improve its screening following other
anamnestic data, and to separate UDAO patients
into “silent asthma” (SA) or “persistent obstruc-
tion”. 
Methods: Patients were subjected to a verbal
questionnaire for the detection of alternative indi-
cation for pulmonary function tests (PFTs), to a
physical examination and, in the case of a severe
smoking habit, to a chest X-ray. PFTs were per-
formed whenever an OLD history or another lung
disease was present and, in the absence of any dys-
pnoea, cough and wheezing, when other symp-
toms and conditions occurred (sputum, chest
tightness, fatigue, rhinitis, snoring; active/passive
smoking, recurrent lower respiratory tract infec-
tions, asthma in childhood or in family, atopy). 
Results: Of 3762 consecutive patients, 1389 pa-
tients with AO were identified. Among them, 147
UDAO patients were detected with no history of
dyspnoea, cough and wheezing (3.9% and 10.6%,
respectively). All these patients had other sugges-
tive symptoms and AO risk factors which justified
PFTs. They presented with mild (65%), moderate
(21%) or even severe (16%) AO. SA patients nor-
malized their spirometric values under treatment.  
Conclusion: The absence of dyspnoea, cough
and wheezing is a fairly frequent finding and a
reason for UDAO. PFTs are warranted with any
suggestive symptoms and AO risk factors. The
favourable follow-up underlines the importance of
screening for UDAO.
Key words: asthma; pulmonary disease; chronic ob-
struction; spirometry; respiratory system abnormalities;
airflow obstruction, undiagnosed airflow obstruction;
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Summary
Abbreviations/definitions
AO airway obstruction
BX bronchodilator
COPD chronic obstructive pulmonary disease
DLCO diffusion capacity of the lung for carbon 
monoxide
FEF 25–75 forced expiratory flow between 25 and 75%
of forced vital capacity
FEV1 forced expiratory volume in 1 second
DFEV1 % pred. variation of the FEV1 expressed in percentage 
of the predicted value (20)
Competing 
interests: 
none declared.
FVC forced expiratory vital capacity
LRTIs lower respiratory tract infections
PFT(s) pulmonary function test(s)
PO “persistent obstruction”
SA “silent asthma”
SA-PO “silent asthma” and “persistent obstruction”
SES socioeconomic status (level 1, 2, or 3)
UDAO undiagnosed airflow obstruction 
Introduction
Obstructive lung disease (OLD) is a health
problem worldwide with a major impact on health
and economics [1]. Studies carried out since the
1990s highlight a prevalence range of undiagnosed
airflow obstruction (UDAO) of 3 to 12% [2–4]. It
may be a manifestation of asthma and chronic ob-
The absence of dyspnoea, cough and wheezing: a reason for undiagnosed airflow obstruction? 426
structive pulmonary disease (COPD), or of a less
frequent disorder [3]. Its screening is biased by the
fact that several patients have never smoked and/or
are asymptomatic [2–4]. Questions remain as to its
frequency, the reasons for its occurrence, the un-
derlying diseases, the type of intervention needed,
and the role of screening [3].
Dyspnoea, cough and wheezes are commonly
associated with airway obstruction (AO) in asthma
and in COPD [1, 5, 6]. However, the diagnosis can
be overlooked if assessed only on clinical grounds.
The lack of correlation between the intensity of
symptoms and the severity of obstruction has been
documented [5–8]. Moreover, both diseases are
poorly perceived by patients and by doctors [2, 3,
5, 9–11]. The need to measure AO for their man-
agement has been mentioned [1–9, 12]. Further
inflammation and remodelling can induce partly
reversible AO at the time the health impairment 
is present [1, 12, 13]. 
AO in the absence of wheezes or/and dyspnoea
has been observed in asthma [5, 7, 12, 14]. In chil-
dren, AO occurring without dyspnoea, cough and
wheezing has been described by Wolf as “silent
asthma” [15]. In adults, the term “silent obstruc-
tion” was introduced for clinical warning purposes,
and also because of the possible absence of these
symptoms in COPD [16–18]. However, patients
referred to, or consulting a pulmonologist, fre-
quently present a respiratory background, such as
smoking and sputum production, which is not
“silent”. 
This prospective study was performed on con-
secutive patients attending for a private pulmono-
logical consultation in Geneva (Switzerland). The
objectives were to detect UDAO in the absence of
three typical AO symptoms, namely, dyspnoea,
cough and wheezing, to improve UDAO screening
following other anamnestic data, to separate
UDAO patients into underlying diseases, mainly,
into “silent asthma” (SA) and “persistent obstruc-
tion” (PO) patients, and to monitor follow-up under
treatment [1, 5–9, 12, 19]. We also queried whether
these atypical patients would become aware of a
functional improvement when treated, and feature
differences in AO reversibility over time. 
Material and methods
Study design: From 1984 to 1997, we examined adults
and elderly patients (≥65 years of age) referred to, or freely
attending the pulmonology practice. In order to detect an
alternative indication for PFTs, patients were subjected to
a verbal questionnaire concerning the purpose of the con-
sultation, current symptoms, the presence or absence of
respiratory symptoms, exercise tolerance, active/passive
smoking, current medical diagnoses and treatment, med-
ical and family history, and socioeconomic status. It was
elaborated by an experienced pulmonologist, but was not
validated in a population-based study. Patients underwent
a physical examination and, in the case of severe smoking
habit, a chest X-ray. 
PFTs were performed whenever an OLD history or
another lung disease was present, and when other sugges-
tive symptoms and clinical conditions, such as AO risk fac-
tors, isolated or in combination were present. Thus, in pa-
tients not presenting the three usual AO symptoms, i.e.
dyspnoea, cough and wheezing, PFTs were also performed
for other indication(s), such as: sputum, inability to bring
out sputum, chest tightness, fatigue, rhinitis, snoring,
fainting, tachycardia, active smoking, passive exposure in
childhood, recurrent lower respiratory tract infections
(LRTIs), LRTIs in childhood, asthma in childhood and/
or in family, atopy, hyperinflation on chest X-ray, and
pre/post-operative evaluation [1–7, 9–13, 15–19]. 
We identified patients with AO as a consequence of
pulmonary function tests (PFTs) [1–19]. Obstruction was
defined as FEV1/FVC ratio below 88% predicted in men
and 89% in women [17]. The level of separation between
asthma and COPD may be difficult to assess [1, 13, 19–22].
We applied the criterion of the variation of the FEV1 ex-
pressed as a percentage of the predicted (% pred.) value,
more than 15% in asthma, and less than 15% in COPD
[20]. DFEV1 % pred. allows estimation of the response to
treatment independent of age, height and sex. Its value is
expected to be low in severe, but also in slight degree ob-
struction. In chronic bronchitis, an asthma-like response
may be featured although less pronounced. Thus, we also
considered a history of smoking, the number of pack-
years, persistent functional anomalies (severe hyperinfla-
tion, FEF 25–75 lower than 20% of predicted, reduced
DLCO), as well as suggestive chest X-ray (hyperinflation,
zones of hyperlucency). 
Patients presenting with both an alternative indica-
tion for a PFT and an UDAO demonstration were in-
cluded and defined the study group. Those presenting an
OLD disease diagnosed in adult life and/or having re-
course to an inhaled therapy were excluded. Approval for
the study was given by the ethics committee of the Asso-
ciation des Médecins du Canton de Genève.  See Appen-
dix for abbreviations/definitions.
Definitions of “silent asthma”, 
“persistent obstruction”, and socioeconomic status
As three usual symptoms of AO were absent, we
adopted a working definition of “silent asthma” (SA)
(DFEV1 % pred. >15%) versus “persistent obstruction”
(PO) (DFEV1 % pred. <15%) on the basis of the DFEV1
% pred. between baseline value at first visit and at 1 to 3
months under treatment [15, 20, 21]. SA and PO patients
composed the SA-PO study group. Definition of socio-
economic status (SES): A Educational levels 1) elementary
level, 2) baccalauréat level and equivalent, 3) university
level; B Professional levels 1) low-level employee, 2) in-
termediate level, 3) executive level. The categorization 
of SES was based on the patient’s educational and pro-
fessional level, and was defined as the higher of the two
levels if these were different.
Lung function testing 
Spirometry was performed by the principal investiga-
tor in an identical manner, according to ATS recommen-
dations. It was made at the first assessment visit, 1 to 3
months after initiation of treatment, and after 2 years
under therapy. Reversibility at first assessment visit was
tested by repeating spirometry after administration of a
bronchodilator (2  200 mg inhaled salbutamol). Func-
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tional improvement under treatment was assessed at base-
line post bronchodilator. Predicted values: European
Coalworkers [19]. Equipment: Gould Godart Pulmonet
III with DLCO (Bilthoven, Netherlands, EU) and Sen-
sorMedics Vmax 229 V6200 Autobox bodyplethysmo-
graph with DLCO (Yorbalinda, California, USA).
Follow-up
For the first follow-up, SA-PO patients were exam-
ined from one to three months after introduction of the
treatment. In case of FEV1 normalization after one month,
the value measured at that time was taken into considera-
tion. Otherwise, the best value of FEV1 obtained one or
two months later was considered. For the second follow-
up, the FEV1 value was considered two years after intro-
duction of the treatment. In the meantime, renewal of
prescriptions and usual follow-up were provided by the
pulmonologist. Several patients also attended the con-
sultation of their general practitioner for other reasons.
Treatment 
Treatment consisted of inhaled beta-agonists (daily
dose 800 mcg salbutamol, or 1000 mcg terbutaline, or 100
mcg salmeterol) and corticosteroids (daily dose 1000 mcg
beclomethasone, or 800 mcg budesonide, or 1000 mcg flu-
ticasone), on a twice-daily schedule [1, 12, 13]. The ther-
apy was not modified during the 2-year follow-up. UDAO
patients were informed of the characteristics of their dis-
ease, the need for better understanding of less sympto-
matic AO, the purpose of the treatment, the side effects
and the necessity for close observance. Oral consent was
obtained for inclusion. Treatment compliance was as-
sessed anamnestically. 
Perception of a functional improvement 
under treatment
Because of a reduced perception of AO in the absence
of three main symptoms, SA-PO patients were evaluated
on their faculty to perceive functional improvement under
treatment. Perception was considered to be present if a
subjective improvement was noticed. It was confirmed by
an affirmative answer to both questions: “Do you feel bet-
ter?”, and “Do you feel that your respiration has im-
proved?” A free report of a better well-being and an affir-
mative answer to additional specific questions were also
considered, such as: “Do you have less sputum?”, “Are you
less tired?”, “Do you have fewer respiratory infections?”;
“Do you have any other observation?” 
Statistical methods
For the 147 patients  included and for the subsample
of 76 patients with complete 2-year follow-up data, a com-
parison of the SA and PO patients with respect to their
FEV1 baseline was first done using the Mann-Whitney-
U-test. Temporal changes in DFEV1 % pred. within
groups were assessed using the sign test and compared
between groups using the Mann-Whitney-U-test. Dif-
ferences in variability of change between groups were
assessed using the Siegel-Tukey-test. Both distributions 
of FEV1 % pred. at given time points, and of temporal
changes in DFEV1 % pred. were represented by box plots
referring to the mentioned subsample (n = 76). The Mann-
Whitney-U-test and the Wilcoxon signed rank test were
used to assess the perception of a functional improvement
under treatment (n = 76). Since our study is descriptive,
no level of significance has been specified. Each p-value
should therefore only be interpreted as the probability that
the observed difference, or an even larger one, would have
arisen by chance alone.
Results
In a cohort of 3762 consecutive patients, 1389
AO patients were identified (figure 1). Among
them, 147 UDAO patients were detected with  no
history of dyspnoea, cough and wheezing: 3.9% of
consecutive patients and 10.6% of patients with
AO (103 adults and 44 elderly patients, age range
18 to 85 years, median 57 years). Median age is
slightly higher in AO and SA-PO patients (table
1). In PO patients, the amount of pack-years is
nearly twice as high as in SA patients (table 2). In
SA-PO male and female patients, SES level 3 is as-
sociated with a higher mean of pack-years than in
levels 1 and 2. 
All SA-PO patients had suggestive symptoms
and clinical conditions, such as AO risk factors,
isolated or in combination, which justified PFTs
(table 3). Table 4 shows the distribution of the 
SA-PO patients according to the severity of AO.
Finally, 23 cases (15.6% of SA-PO patients) were
associated with a severe degree of AO. There was
no apparent difference between adults and elderly
patients, or between men and women. 
We could define 68 cases of SA (age range 16
to 85 years, median age 56) and 79 cases of PO (age
range 33 to 78 years, median age 58). Not all PO
patients with severe obstruction were smokers
[1–4]. In addition, some PO smokers showed a
good response to treatment (DFEV1 % pred. close
All consecutive patients
n = 3762
Patients with airway obstruction
n = 1389
Patients with
Silent asthma    Persistent obstruction
n = 68                                   n = 79
(baseline)
1st follow-up
(1–3 months)
        SA                        PO
     n = 62                  n = 61
2nd follow-up
(2 years)
        SA                        PO
     n = 44                   n = 32
Figure 1
Flow chart describing
selection of study
sample and follow-up.
The flow chart de-
scribes the selection
process having led 
to the study sample 
of UDAO patients 
with silent asthma 
(SA) or persistent
obstruction (PO). 
Moreover, it shows 
the number of pa-
tients in each of the
two study subgroups
having participated 
in a given follow-up 
assessment. Among
the 76 patients as-
sessed after 2 years
(52%), none had
skipped the first fol-
low-up assessment. 
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to 15%, or above) as observed in chronic bron-
chitis [1]. Even though 55 PO patients presented
COPD features, we refrained from defining an
additional category, as overlap between asthma 
and COPD needs accurate investigation [22]. We
maintained the more general expression “persist-
ent obstruction” for the whole of the less respon-
sive group. 
At 1 to 3 months after initiation of treatment,
the SA group emerged as evidenced by the normal-
isation of the mean value of FEV1 and by a mean
DFEV1 % pred. of 25%. After 2 years’ follow-up,
the DFEV1 % pred. remained higher for the SA
than for the PO patients. Median values of FEV1
% pred. were higher among SA than among PO
within the subsample of 76 patients with complete
follow-up data (SA n = 44, PO n = 32) (figure 2).
The values increased until the first follow-up as-
sessment, and tended to drop slightly in both
groups between the first and the second follow-up
assessment. This decrease in FEV1 % pred. mean
values was not associated with a recurrence of ini-
tial symptoms or with clinical worsening. No ap-
parent difference between adults and elderly pa-
tients could be discerned.
The median increase in DFEV1 % pred. post
bronchodilator assessment was higher in the SA
than in the PO group (figure 3). In SA, it contin-
ued to be slightly steeper in the second time inter-
val. The decrease in DFEV1 % pred. between the
all patients AO patients SA-PO patients
(n = 3762) (n = 1389) (n = 147)
median1 median1 median1
(quartiles) (quartiles) (quartiles)
all 50 54 57
(n = 3762, 1389, 147) (34, 63) (38, 65) (45, 64)
men 51 56 55
(n = 1792, 766, 79) (36, 64) (41, 66) (43, 62)
women 49 52 58
(n = 1970, 623, 68) (33, 63) (35, 65) (48, 65)
all smokers 55 59 56
(n = 1387, 718, 95) (40, 66) (48, 68) (46, 64)
male smokers 57 59 55
(n = 818, 460, 60) (43, 68) (48, 68) (45, 62)
female smokers 52 58 58
(n = 569, 258, 35) (35, 65) (43, 67) (48, 65) 
1 medians and quartiles of age
Patients attending a pulmonology practice from 1984 to 1997. 1) Collective: all consecutive patients, 
2) AO patients: patients with airway obstruction (as a part of the collective), mainly asthma 
and chronic obstructive pulmonary disease patients, 3) SA-PO patients: “Silent asthma” 
and “Persistent obstruction” patients (as a part of the AO patients). 
Table 1
Demographic data.
Smokers SA-PO patients SA patients PO patients
(n = 95) (n = 39) (n = 56)
median1 median1 median1
(quartiles) (quartiles) (quartiles)
all 40 25 47.5
(n = 95, 39, 56) (25, 50) (10, 40) (36.5, 60)
men 40 30 45
(n = 60, 23, 37) (25, 52.5) (10, 40) (40, 60)
women 35 22.5 50
(n = 35, 16, 19) (25, 50) (10, 35) (35, 55)
SES 1 40 25 45
(n = 54, 16, 38) (25, 50) (12.5, 35) (35, 55)
SES 2 35 20 57.5
(n = 25, 13, 12) (20, 60) (10, 35) (41, 60)
SES 3 52 58 58
(n = 16, 10, 6) (25, 50) (15, 50) (40, 55) 
1 medians and quartiles of pack-years smoked
SA–PO patients: “Silent asthma” (SA) and “Persistent obstruction” (PO) patients. 
Number of smokers n = 95, representing 65% of the SA–PO patients (first assessment visit: n = 147).
SES: socioeconomic status categorized based on educational level (1) elementary level, 2) baccalauréat 
level and equivalent, 3) university level) and professional level (1) low-level employee, 2) intermediate level, 
3) executive level). SES was defined as the higher of the two levels if those were different.
Table 2
Smoking history
(pack-years), gender
and socioeconomic
status.
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Suggestive symptoms1 Clinical conditions1
“Silent “Persistent “Silent “Persistent 
asthma” obstruction” asthma” obstruction”
n = 68 n = 79 n = 68 n = 79
Fatigue 13 17 Recurrent LRTIs 19 15
Chest tightness 19 15 LRTIs in childhood 18 15
Burning sensation 3 5 Active smoking 47 71
Tachycardia 3 3 Passive smoking 7 28
exposure in childhood
Rhinitis 15 5 Asthma in childhood 6 1
Sputum production 19 46 Asthma in family 16 14
Inability to bring 9 Pre/post-operative 12 8
out sputum evaluation
Fainting 3 * Hyperinflation 61
on chest X-ray
Snoring 1 8 ** Known atopy 6 1
1 expressed in percentage of “silent asthma” patients (SA) and of “persistent obstruction” patients (PO). 
* was associated with severe air trapping and hyperinflation.
** was associated with sleep apnea obstructive syndrome.
LRTIs: lower respiratory tract infections. PFTs: pulmonary function tests.
Table 3
Alternative indication
for performing PFTs
in UDAO screening.
Severity of Slight Moderate Severe
obstruction n = 93 n = 31 n = 23
FEV1 at first visit >69% pred. 50–69% pred. <50% pred.
“Silent asthma”, n = 68 78% 16% 6%
“Persistent obstruction”, n = 79 51% 25% 24%
SA-PO patients, n = 147 63% 21% 16%
Percentage of patients across different severity levels of airway obstruction [19]. 
SA-PO patients: patients with airway obstruction, presenting without any dyspnoea, cough, 
and wheezing, and subdivided in “silent asthma” and “persistent obstruction” patients. 
FEV1 = forced expiratory volume in 1 second. % pred. = percentage of predicted value.
Table 4 
Severity of airway
obstruction seen at
first assessment visit.
Figure 2
Variability of FEV1 % pred. at four assessment
times.
“Silent asthma” (SA) and “Persistent obstruc-
tion” (PO) patients with complete follow-up
data, n = 76. FEV1 % pred.: forced expiratory
volume in 1 second expressed as percentage 
of predicted value. For each group, the distri-
bution of the variable FEV1 % pred. at different
times is represented by four box plots, indicat-
ing the minimum and the maximum values
(end points of the two whiskers), the lower
quartile (lower end of the box), the median
(horizontal line within the box) and the upper
quartile (upper end of the box). Observed me-
dians: a) initial assessment: SA 80.0, PO 66.0, 
p = 0.002; b) post bronchodilator assessment:
SA 93.5, PO 75.5, p = 0.0004; c) 1–3 months’ 
follow-up: SA 102.0, PO 79.5, p <0.0001; 
d) 2 years’ follow-up: SA 99.0, PO 75.0, 
p <0.0001. P-values obtained from 
Mann-Whitney-U-test. 
FE
V
1 
%
 p
re
d
ic
te
d
baseline
pre            post
bronchodilator
silent asthma persistent obstruction
after 1–3
months
after
2 years
baseline
pre            post
bronchodilator
after 1–3
months
after
2 years
two follow-ups was the same in both groups. The
variability of change between post bronchodilator
assessment and the first follow-up was higher
among SA than among PO patients. Thus, SA
emerges as a clinical entity featuring specific char-
acteristics, namely: 1) a different follow-up under
treatment in regards to FEV1 and DFEV1 % pred.
mean values, 2) a lower incidence of smoking, and
3) far less sputum production (tables 2 and 4, fig-
ures 1 to 4).
At 1 to 3 month follow-up, a lack of compli-
ance due to side effects was observed in 23 cases.
We included these in our subdivision: 5 non-smok-
ing SA patients featured a DFEV1 % pred. value
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Figure 3
Variability of change in DFEV1 % pred. between
different assessment times.
“Silent asthma” (SA) and “Persistent obstruc-
tion” (PO) patients with complete follow-up
data, n = 76. DFEV1 % pred.: variation of forced
expiratory volume in 1 second expressed as
percentage of the predicted value (ref. [20]).
For each group, the distribution of the change
in DFEV1 % pred. between different assessment
times is represented by three box plots (see
figure 2). Observed median changes in DFEV1 %
predicted: a) between initial and post bron-
chodilator assessment: SA 13.5, p <0.0001, 
PO 9.0, p <0.0001, with p = 0.004 for difference
between groups; b) between post broncho-
dilator assessment and 1–3 months’ follow-up: 
SA 9.0, p <0.0001, PO 4.5, p = 0.0002, with 
p = 0.13 for difference between groups; 
c) between 1–3 months’ and 2 years’ follow-up:
SA - 4.0, p <0.0001, PO - 4.0, p = 0.0005, with 
p = 0.60 for difference between groups. 
P-values obtained using the sign test and 
the Mann-Whitney-U-test, respectively. 
Variability of change in DFEV1 % pred. between
post bronchodilator and first follow-up assess-
ment differed between the two groups 
(p = 0.02, Siegel-Tukey-test). 
n = 33
n = 20
1–3 months
n = 20
n = 11
n = 12
n = 11
n = 12
1–3 months sraey 2 tAsraey 2 tA
40
30
20
10
0
clinical improvement
perceived
clinical improvement
not perceived
n = 33
Figure 4
Perception of a functional improvement under treatment.
“Silent asthma” (SA, white) and “Persistent obstruction” (PO, black)
patients with complete follow-up data, n = 76. DFEV1 % pred.: variation 
of forced expiratory volume in 1 second expressed as percentage of the
predicted value (ref. [20]). For perception definition, see Material and
Methods. For the two groups, mean values of DFEV1 % pred. are given
for different assessment times. I) A Patients with perceived clinical im-
provement: a) at 1–3 months’ follow-up: SA 30, PO 19, p = 0.003; b) at 2
years’ follow-up: SA 26, PO 14, p = 0.002. B Patients without perceived
clinical improvement: a) at 1–3 months’ follow-up: SA 20, PO 9 , p = 0.008;
b) at 2 years’ follow-up SA 15, PO 4, p = 0.01 (p-values obtained from
Mann-Whitney-U-test). II) Changes in DFEV1 % pred. between the two fol-
low-up assessments reached the following p-values (Wilcoxon signed
rank test): a) SA patients in group A: p <0.0001; b) PO patients in group 
A: p <0.0001; c) SA patients in group B: p = 0.02; d) PO patients in group
B: p = 0.02. III) Differences in DFEV1 % pred. after 2 years of follow-up
between groups A and B reached the following p-values (Mann-Whitney-
U-test): p = 0.02 in SA patients and p = 0.001 in PO patients. The corre-
sponding p-values for the comparison after 1–3 months of follow-up
were 0.05 and 0.0007, respectively.
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patients with patients with patients with 1 to 
2 years follow-up incomplete follow-up 3 months follow-up 
mean1 (n) mean1,2 (n) mean1,2 (n)
PO patients
baseline 64 (32) 73 (47) (p = 0.05) 68 (29) (p = 0.41)
pre bronchodilator
baseline 74 (32) 82 (47) (p = 0.04) 77 (29) (p = 0.29)
post bronchodilator
after 1 to 3 months 80 (32) 80 (29) (p = 0.67) 80 (29) (p = 0.67)
SA patients
baseline 78 (44) 83 (24) (p = 0.40) 83 (18) (p = 0.43)
pre bronchodilator
baseline 92 (44) 96 (24) (p = 0.51) 95 (18) (p = 0.71)
post bronchodilator
after 1 to 3 months 105 (44) 102 (18) (p = 0.41) 102 (18) (p = 0.41)
1 mean of FEV1 in percent of predicted 
2 p-values from Mann-Whitney-U-test, reference group = patients with complete follow-up (2 years)
Patients with incomplete follow-up tended to start from higher FEV1 values than patients with a 2-year 
follow-up (n = 76).
PO patients: “persistent obstruction” patients
SA patients: “silent asthma” patients
Table 5
Comparison of FEV1
% predicted between
subjects with and
without complete
follow-up.
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higher than 15%, and 18 heavy smoking PO pa-
tients low to very low FEV1 and DFEV1 % pred.
values, as well as hyperinflation (PFTs, chest X-
ray). Before the end of 2 year follow-up, we failed
to keep track of 48 patients for similar reasons, or
because they felt well enough to deny the disease,
or because some physicians stopped the treatment
in the absence of symptoms. Also, patients with in-
complete follow-up tended to start from higher
FEV1 values than patients with a 2-year follow-up
(table 5). 
In SA patients with perception of functional
improvement, DFEV1 % pred. was high at first fol-
low-up assessment and remained high later (figure
4). We made the same observation for PO patients,
although with lower DFEV1 % pred. In this group,
some patients responded to therapy as seen in
chronic bronchitis but could not be classified as
SA. This was characterized by a mean DFEV1 %
pred. of 19%, lower than the mean value of 30%
seen in SA, featuring some overlap between SA and
PO patients (figures 2 and 3). DFEV1 % pred. of
patients with no perception of improvement was
lower for both groups at 1 to 3 month follow-up
and even worse after two years. 
Discussion
This study illustrates the outcome of UDAO
occurring without dyspnoea, cough and wheezing.
To our knowledge, it is the first attempt to describe
this situation in a private pulmonology practice.
The condition was identified in 10.6% of the pa-
tients with AO and in 3.9% of the collective. The
prevalence may be higher in an unbiased setting as
seen in the cohort SAPALDIA: 5.4% [18]. Al-
though our data should not be compared to a pop-
ulation-based study, both results highlight that the
lack of these symptoms is not rare. It is a reason for
UDAO, mainly in SA. AO seen in PO patients, as-
sociated with smoking and sputum, might have
been previously diagnosed [1, 6]. The absence of
treatment before inclusion induced discomfort, fa-
tigue, recurrent infections and limitation in the
quality of life [1, 12, 15, 16, 19, 23, 24]. 
A poor correlation between the intensity of
usual symptoms and the OLD severity has been
mentioned [1, 5–9, 11, 12, 16, 18, 25–30]. Teeter
et al. extended this discordance to nocturnal awak-
ening, chest tightness and sputum production, de-
scribing “underestimator patients” [7]. However,
there are reasons for performing PFTs in the ab-
sence of usual AO symptoms (table 3) [1–7, 9,
11–13, 15–19, 28–31]. Sputum for instance, largely
present in PO, highlights its belonging to COPD
main symptoms [1, 5–7, 13, 14, 19]. Concerning
fatigue, a relationship has been shown between its
intensity and pulmonary function, exercise toler-
ance, or quality of life [15, 32]. As even a mild
disease may compromise the quality of life, other
anamnestic data have to be considered for improv-
ing UDAO screening [33]. 
A less symptomatic AO is not necessarily asso-
ciated with a slight degree of AO. SA-PO patients
presented with moderate or even severe AO (table
4). This observation was seen in adults and elderly
patients. Thus, UDAO is related to a higher-than-
expected AO degree [2–4, 16, 26, 29]. The clinical
implications are high. For instance, the risks for
surgery performed under general anaesthesia are
underestimated if an underlying obstructive dis-
ease is not diagnosed [1, 16]. Other risks, such as
increased morbidity and mortality, have also been
mentioned [2–4]. Finally, misdiagnosed lung vol-
ume anomalies might serve as a base for further
respiratory impairment, infections and failure [1,
3, 12, 19, 34]. It is of primordial interest that the
new COPD classification mentions that some pa-
tients do not experience AO symptoms [1].
The treatment could not be standardized
because of the subsequent introduction of budeso-
nide, salmeterol and fluticasone. Also, there was a
fairly high drop-out rate over time (48%). These
facts may limit our ability to draw conclusions
from the response seen in each group. However, a
separation into SA and PO patients could be made,
featuring specific characteristics for the under-
lying diseases which is an objective of UDAO
screening [2–4, 20–22]. SA emerged as a clinical
entity with relevance in adults also (tables 2 and 4,
figures 1 to 4). SA patients normalized their spiro-
metric values, whereas PO patients did not [1, 12,
13, 19]. On average, both groups showed a de-
crease in FEV1 % pred. suggestive of altered AO
reversibility and potential ongoing remodelling 
[1, 12, 13] (figures 2 and 3). 
For most SA-PO patients, the evolution was
clinically good. This study also highlights the ne-
cessity of a treatment as a decisive intervention [1,
12, 13, 21, 22, 29]. As for asthma, SA patients have
to be evaluated following remission versus relapse
[12]. About 20% could interrupt medication after
two years’ follow-up. However, 80% had to main-
tain it due to a relapse, preceded by an asympto-
matic decrease in FEV1 and DFEV1 % pred. mean
values (figures 2 to 4) corresponding to persistent
asthma [12]. As for COPD, PO patients have to be
assessed following the response. Bronchodilators
should not be discontinued [1]. Further studies will
better define indication to inhaled corticosteroids
[1, 13]. The favourable follow-up underlines the
importance of UDAO screening but points to its
financial impact [2–4].  
Less symptomatic AO raises the issue of non-
perceiving variations in AO. Reduced perception
of dyspnoea was described in asthma and in COPD
The absence of dyspnoea, cough and wheezing: a reason for undiagnosed airflow obstruction? 432
[1–11, 30]. A slow increment in bronchoconstric-
tion could induce subjective adaptation to AO [27].
Habituation to symptoms might account for
blunted perception of progressive AO [25]. Re-
duced afferent information, impaired perception
of airway tone, and brain centre defect could be in-
volved in a decreased cough reflex [9, 11, 26]. Air-
flow limitation may precede the onset of wheez-
ing, and some explanations have been proposed for
its absence [5, 14, 15, 35]. Research on less symp-
tomatic AO also focuses on the psychological
mechanisms by which symptoms are perceived [9,
28, 36, 37]. 
In this study, differences in AO perception lev-
els have been found under treatment. Although the
evaluation could be carried out in only 76 SA-PO
patients (52%), it suggests a correlation with the
response expressed by the DFEV1 % pred. (figure
4). Patients showing no perception of improve-
ment belong to the group with the lowest increase
of DFEV1 % pred., in comparison with patients
showing a perception. The absence of perception
of improvement is associated with lesser increases
of FEV1. This fact also suggests that a small vari-
ation in AO is related to a lesser perception [9, 10,
27]. 
Reduced perception of AO, even by the physi-
cian, is a striking predicament. It appears to be one
reason for the drop-out seen in our study, and an-
other one for UDAO [2–3, 5, 7–12, 15, 16, 25–28].
For instance, AO has been described as common
but unsuspected by physicians working in a gen-
eral medical service [38]. Moreover, many UDAO
patients had reported AO symptoms without any
subsequent diagnosis [2–4]. Therefore, UDAO
screening should be improved, especially among
non-smokers, by systematic PFTs in the presence
of any suggestive symptoms and of AO risk factors,
mainly: passive smoking in childhood or adult life,
recurrent LRTIs, asthma in childhood and/or in
family, rhinitis, and atopy [1–4, 9, 12, 13, 18–19,
31, 39–41].  
We conclude that the occurrence of AO in the
absence of three main symptoms, i.e. dyspnoea,
cough and wheezing, is a fairly frequent finding
and a reason for UDAO. It is associated with slight,
moderate or even severe AO. The value of DFEV1
% pred. is of clinical interest in identifying UDAO
patients, particularly those with SA. This paedi-
atric entity has thus also developed a clinical rele-
vance in adults. Risk factors for UDAO include
smoking and other causes, such as reduced AO per-
ception by patients and even by physicians. There-
fore, UDAO screening should be improved, espe-
cially among non-smokers. The decision regard-
ing long-term treatment must be defined on the
basis of response, follow-up and clinical experi-
ence.
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